Cargando…

KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location

Colorectal cancer (CRC) is characterized by complex interplay between macroenvironmental factors and tumour microenvironment, leading to variable outcomes in CRC patients. To date, there is still a need to identify macroenvironment/microenvironment factors that could define subgroup of patients that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabuso, M., Christian, M., Kimani, P. K., Gopalakrishnan, K., Arasaradnam, R. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471139/ https://www.ncbi.nlm.nih.gov/pubmed/32594310 http://dx.doi.org/10.1007/s12253-020-00850-y

Ejemplares similares

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
por: Xie, Ming-zhi, et al.
Publicado: (2019)

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
por: Cao, De-Dong, et al.
Publicado: (2017)

KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
por: Phipps, A I, et al.
Publicado: (2013)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Fibrotic Phenotype of Peritumour Mesenteric Adipose Tissue in Human Colon Cancer: A Potential Hallmark of Metastatic Properties
por: Tabuso, Maria, et al.
Publicado: (2021)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Role of tissue microenvironment resident adipocytes in colon cancer
por: Tabuso, Maria, et al.
Publicado: (2017)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

The effect of the 2-week wait referral system on the detection of and mortality from colorectal cancer: protocol of a systematic review and meta-analysis
por: Mozdiak, Ella, et al.
Publicado: (2016)

Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases
por: Sakai, Nozomu, et al.
Publicado: (2021)

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
por: Lucchetti, Donatella, et al.
Publicado: (2021)

Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma
por: La Salvia, Anna, et al.
Publicado: (2022)

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival
por: Brouwer, Nelleke P. M., et al.
Publicado: (2019)

Practical Implications of KRAS Mutation Status and Sidedness of Primary Tumour in Patients with Colorectal Cancer and Synchronous Liver Metastases: A Subset Analysis of the CoSMIC Study
por: Chan, Anthony K. C., et al.
Publicado: (2022)

Is it possible to predict the side of hepatic metastases according to the primary location of colorectal cancer?
por: Çoruh, Ayşegül Gürsoy, et al.
Publicado: (2020)

Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation
por: Pinheiro, Manuela, et al.
Publicado: (2015)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
por: Benavides, Manuel, et al.
Publicado: (2019)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
por: Montomoli, Jonathan, et al.
Publicado: (2012)

KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
por: GUTIÉRREZ, CRISTINA, et al.
Publicado: (2013)

Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
por: Takayama, Yuji, et al.
Publicado: (2018)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
Publicado: (2020)

Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
por: Sagawa, Tamotsu, et al.
Publicado: (2020)

Impact of primary tumour location on colorectal liver metastases: A systematic review
por: Bingham, George, et al.
Publicado: (2020)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation
por: Pang, Xue-Lian, et al.
Publicado: (2017)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
por: Poad, Heather, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a475hraemdb1de0d5c51hbpidf